Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 16/20 | 0.79 |
| ▸ | ITGA2B | P08514 | 16/20 | 0.79 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.45 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7292028 | 0.91 | ITGB3 (0.82) | ITGB3ITGA2BF10F2PLG | |
| SCHEMBL7284349 | 0.91 | ITGB3 (0.82) | ITGB3ITGA2BF10F2PLG | |
| SCHEMBL7276503 | 0.91 | ITGB3 (0.73) | ITGB3ITGA2B | |
| SCHEMBL8880911 | 0.89 | ITGB3 (0.78) | ITGB3ITGA2B | |
| Lamifiban SCHEMBL871446 | 0.88 | ITGB3 (1.00) | ITGB3ITGA2BF2PLG | |
| Lamifiban SCHEMBL4683 | 0.88 | ITGB3 (1.00) | ITGB3ITGA2BF2PLG | |
| SCHEMBL7282972 | 0.88 | ITGB3 (0.86) | ITGB3ITGA2BF10F2 | |
| SCHEMBL8379088 | 0.86 | ITGB3 (0.78) | ITGB3ITGA2B | |
| SCHEMBL7294041 | 0.86 | ITGB3 (0.78) | ITGB3ITGA2B | |
| SCHEMBL7293550 | 0.84 | ITGB3 (0.68) | ITGB3ITGA2BF10F2PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576071-B2 | Antithrombotic compound | SANOFI-AVENTIS (FR) | 2009-08-18 | — | — | US | disclosed |
| US-20070293442-A1 | ANTITHROMBOTIC COMPOUND | SANOFI-AVENTIS (FR) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293442-A1 | ANTITHROMBOTIC COMPOUND | F13B, SERPINC1, SELP | ITGB3 66/4885ITGA2B 13/4885GAA 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.